Stocktoria
Protalix BioTherapeutics, Inc. PLX
Protalix BioTherapeutics, Inc. (PLX) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $52.7M at a -12.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -0.17 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.488 |
| Retained earnings / assets | -4.675 |
| EBIT / assets | -0.067 |
| Equity / liabilities | 1.414 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PLX | Protalix BioTherapeutics, Inc. | 2/9 | -11.01 | — | -1.2% |
| IVVD | Invivyd, Inc. | 2/9 | -0.36 | — | +110.5% |
| CSBR | CHAMPIONS ONCOLOGY, INC. | 5/9 | -7.27 | — | +4.4% |
| FENC | FENNEC PHARMACEUTICALS INC. | — | -4.88 | — | -6.1% |
| CHRS | Coherus Oncology, Inc. | 4/9 | — | 1.4 | +59.8% |
| EDIT | Editas Medicine, Inc. | 1/9 | — | — | +25.4% |
| VYGR | Voyager Therapeutics, Inc. | 1/9 | -1.03 | — | -49.5% |
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
FAQ
Is PLX financially healthy?
Protalix BioTherapeutics, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does PLX pay a dividend?
No, Protalix BioTherapeutics, Inc. does not currently pay a dividend.
How profitable is PLX?
In FY2025, Protalix BioTherapeutics, Inc. had a net margin of -12.5% and a return on equity of -13.7%.
What is the analyst price target for PLX?
The average Wall-Street price target for Protalix BioTherapeutics, Inc. is $11.00, about 319.8% above the recent price, from 2 analysts.
Is PLX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Protalix BioTherapeutics, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.